pembrolizumabRecent, repeatedEvidence- NCT07762703 · BreakBio Corp · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2026
- NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07679360 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Pembrolizumab injection” · registered Jun 2026
- NCT06618287 · Bristol-Myers Squibb · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2024
- NCT06249048 · Strand Therapeutics Inc. · Phase 2 · live · background · “Keytruda®” · registered Feb 2024
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 1111 studies | 1010 studies | background 14 · comparator 2 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07544056 · BeBetter Med Inc · Phase 3 · live · background · “Carboplatin Injection” · registered Apr 2026
- NCT06966700 · Merck & Co., Inc · Phase 3 · live · background · “Carboplatin” · registered May 2025
- NCT06926868 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Carboplatin” · registered Apr 2025
- NCT06841354 · Merck & Co., Inc · Phase 3 · live · comparator · “Carboplatin” · registered Feb 2025
- NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Carboplatin” · registered Feb 2025
| Eli Lilly and Company16% of its industry studies | 1013 studies | 911 studies | comparator 7 · background 21 |
Albumin-Bound PaclitaxelRecent, repeatedEvidence- NCT07729956 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Jul 2026
- NCT07281976 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “albumin-bound Paclitaxel injection” · registered Dec 2025
- NCT06841354 · Merck & Co., Inc · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Feb 2025
- NCT06767527 · Akeso · Phase 3 · live · background · “Nab-paclitaxel” · registered Jan 2025
- NCT06419621 · BioNTech SE · Phase 3 · live · background · “Nab-Paclitaxel” · registered May 2024
| Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008) | 911 studies | 911 studies | comparator 5 · background 22 |
GemcitabineRecent, repeatedEvidence- NCT07544056 · BeBetter Med Inc · Phase 3 · live · background · “Gemcitabine Hydrochloride for Injection” · registered Apr 2026
- NCT07533123 · Alphamab Oncology · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection” · registered Mar 2026
- NCT06926868 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2025
- NCT06841354 · Merck & Co., Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Feb 2025
- NCT06519370 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine” · registered Jul 2024
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 910 studies | 89 studies | comparator 8 · background 14 |
CapecitabineRecent, repeatedEvidence- NCT07679360 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Capecitabine tablets” · registered Jun 2026
- NCT07533123 · Alphamab Oncology · Phase 3 · live · comparator · “Capecitabine Tablets” · registered Mar 2026
- NCT06966700 · Merck & Co., Inc · Phase 3 · live · background · “Capecitabine” · registered May 2025
- NCT06926868 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Capecitabine” · registered Apr 2025
- NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Capecitabine” · registered Feb 2025
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 911 studies | 78 studies | comparator 10 · background 8 |
PaclitaxelRecent, repeatedEvidence- NCT07111832 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel for Injection” · registered Aug 2025
- NCT06966700 · Merck & Co., Inc · Phase 3 · live · background · “Paclitaxel” · registered May 2025
- NCT06926868 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Paclitaxel” · registered Apr 2025
- NCT06841354 · Merck & Co., Inc · Phase 3 · live · comparator · “Paclitaxel” · registered Feb 2025
- NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Paclitaxel” · registered Feb 2025
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 811 studies | 810 studies | comparator 9 · background 21 |
eribulinRecent, repeatedEvidence- NCT06519370 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Eribulin” · registered Jul 2024
- NCT06449222 · BioNTech SE · Phase 2 · live · background · “Eribulin” · registered Jun 2024
- NCT06279364 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 · live · comparator · “Eribulin” · registered Feb 2024
- NCT02555657 · Merck & Co., Inc · Phase 3 · comparator · “eribulin” · registered Sep 2015
| Eisai Co., Ltd.87% of its industry studiesUS: off-patent, 10 generics marketedEU: off-patent, 2 generics authorized | 33 studies | 33 studies | comparator 3 · background 1 |
toripalimabRecent, repeatedEvidence- NCT07281976 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · comparator · “Toripalimab Injection” · registered Dec 2025
- NCT07111832 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Toripalimab Injection” · registered Aug 2025
- NCT05955105 · Innolake Biopharm · Phase 2 · live · background · “Toripalimab” · registered Jul 2023
| RemeGen Co., Ltd.15% of its industry studiesUS: Coherus Biosciences, Inc. (FDA 2023)EU: Topalliance Biosciences Europe Limited (EMA 2024) | 33 studies | 33 studies | comparator 2 · background 1 |
sacituzumab govitecanRecent, repeatedEvidence- NCT07533123 · Alphamab Oncology · Phase 3 · live · comparator · “Sacituzumab Govitecan for Injection” · registered Mar 2026
- NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Sacituzumab Govitecan-hziy” · registered Apr 2023
- NCT05113966 · Pharmacosmos A/S · Phase 2 · background · “Sacituzumab Govitecan-hziy” · registered Oct 2021
- NCT05008510 · Veru Inc. · Phase 2 · comparator · “Sacituzumab Govitecan-hziy” · registered Aug 2021
- NCT04927884 · ImmunityBio, Inc. · Phase 2 · background · “Sacituzumab Govitecan-Hziy” · registered Jun 2021
| Gilead Sciences77% of its industry studiesUS: IMMUNOMEDICS INC (FDA 2020)EU: Gilead Sciences (EMA 2021) | 22 studies | 22 studies | background 3 · comparator 2 |
VinorelbineRecent, repeatedPhase 4 trial recordedEvidence- NCT07533123 · Alphamab Oncology · Phase 3 · live · comparator · “Vinorelbine Tartrate Injection” · registered Mar 2026
- NCT06519370 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Vinorelbine” · registered Jul 2024
- NCT02555657 · Merck & Co., Inc · Phase 3 · comparator · “vinorelbine” · registered Sep 2015
- NCT02225470 · Eisai Co., Ltd. · Phase 3 · comparator · “Vinorelbine injection” · registered Aug 2014
| Eli Lilly and Company9% of its industry studies | 22 studies | 22 studies | comparator 4 |
IpilimumabRecent, repeatedEvidence- NCT07762703 · BreakBio Corp · Phase 2 · live · background · “Ipilimumab 2.5 mg” · registered Aug 2026
- NCT05933265 · Lantern Pharma Inc. · Phase 2 · live · background · “Nivolumab & Ipilimumab” · registered Jun 2023
- NCT03241173 · Incyte Corporation · Phase 2 · background · “Ipilimumab” · registered Aug 2017
- NCT03126110 · Incyte Corporation · Phase 2 · background · “Ipilimumab” · registered Apr 2017
| Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011) | 22 studies | 22 studies | background 4 |
olaparibRecent, repeatedEvidence- NCT06966700 · Merck & Co., Inc · Phase 3 · live · background · “Olaparib” · registered May 2025
- NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Olaparib (if approved/available locally)” · registered Feb 2025
- NCT05933265 · Lantern Pharma Inc. · Phase 2 · live · background · “Olaparib” · registered Jun 2023
| AstraZeneca76% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2014) | 23 studies | 22 studies | background 3 |
Antineoplastic AgentsRecent, repeatedEvidence- NCT07556848 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3 · live · comparator · “Chemotherapy” · registered Apr 2026
- NCT07108309 · Biocad · Phase 2 · live · background · “Chemotherapy” · registered Aug 2025
| — | 22 studies | 22 studies | comparator 1 · background 1 |
CyclophosphamideRecent, repeatedEvidence- NCT06966700 · Merck & Co., Inc · Phase 3 · live · comparator · “Cyclophosphamide” · registered May 2025
- NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Cyclophosphamide” · registered Feb 2025
- NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
- NCT05112536 · Pharmacosmos A/S · Phase 2 · background · “Cylophosphamide” · registered Oct 2021
- NCT04927884 · ImmunityBio, Inc. · Phase 2 · background · “Cyclophosphamide” · registered Jun 2021
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 23 studies | 11 study | comparator 1 · background 13 |